Macomics has a portfolio of antibody programs progressing towards the clinic. Our portfolio is diversified by the mechanism of action and is focussed on multi-hit biological hypothesis, modulating both TAM biology directly and the activity of the broader immune system, to re-invigorate immune responses against cancer cells.A key challenge in the field has been the translation of large Omic datasets into validated drug targets,...
Macomics has a portfolio of antibody programs progressing towards the clinic. Our portfolio is diversified by the mechanism of action and is focussed on multi-hit biological hypothesis, modulating both TAM biology directly and the activity of the broader immune system, to re-invigorate immune responses against cancer cells.A key challenge in the field has been the translation of large Omic datasets into validated drug targets, due to the lack of representative cell models. This requires the use of low throughput human monocyte-derived macrophage assays, which are unsuitable for target validation or drug testing at scale
Sponsored Ad
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.